Vericel to Report Third-Quarter 2020 Financial Results on November 5, 2020
22 October 2020 - 11:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced the following webcast and conference call to discuss its
third-quarter 2020 financial results and business highlights.
What: |
Vericel Corporation Third-Quarter 2020 Earnings Call |
When: |
Thursday, November 5, 2020 at
8:30am (EDT) |
Where: |
http://investors.vcel.com/events-presentations |
How: |
The conference call will be
available live in the Investors section of the Vericel website at
http://investors.vcel.com/events-presentations. Please access
the site at least 15 minutes prior to the scheduled start time in
order to download the required audio software if necessary.
Presentation slides for the conference call will be available on
the webcast and in the Investor Relations section of the Vericel
website. |
To participate in the live call by telephone, please call (877)
312-5881 and reference Vericel Corporation second-quarter 2020
earnings call. If calling from outside the U.S., please use the
international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast
will be available at http://investors.vcel.com/events-presentations
until November 5, 2021. A replay of the call will also be available
until 11:00am (EDT) on November 12, 2020 by calling (855) 859-2056,
or from outside the U.S. (404) 537-3406. The conference ID is
5426489.
About Vericel CorporationVericel is a leader in
advanced therapies for the sports medicine and severe burn care
markets. The company markets two cell therapy products in the
United States. MACI® (autologous cultured chondrocytes on porcine
collagen membrane) is an autologous cellularized scaffold product
indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Epicel® (cultured epidermal autografts) is a
permanent skin replacement for the treatment of patients with deep
dermal or full thickness burns greater than or equal to 30% of
total body surface area. The company also holds an exclusive
license for North American commercial rights to NexoBrid®, a
registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the
company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. NexoBrid® is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2020 Vericel
Corporation. All rights reserved.
Investor Contact:Lee SternSolebury
Troutlstern@troutgroup.com+1 646-378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024